The acquisition of the malignant phenotype requires a multitude of complex processes, including a loss of control of cell proliferation (e.g. via oncogene activation), higher metabolic requirements and the ability of cells to invade and metastasize throughout the body (reviewed in Evans, 1991) . The processes of tumour cell invasion and metastasis are likely to involve the inappropriate expression of proteinases (reviewed in Mignatti and Rifkin, 1993) . The serine proteinases of the plasminogen activation proteolytic cascade appear to play an important role in this process (reviewed in Duffy, 1993; Mignatti and Rifkin, 1993) . Plasminogen, a broad-spectrum serine endopeptidase zymogen, is secreted in its mature form as a single-chain glycoprotein containing a N-terminal glutamic acid, a binding domain [consisting of five kringle structures on which the lysine binding sites (kringles 1, 4 and 5) are located] and a protease domain (reviewed in Castellino, 1995) . When activated by urokinase plasminogen activator (uPA) or tissue plasminogen activator, plasminogen is converted into the active twin-chain proteinase, i.e. plasmin (Castellino, 1995) . It is clear that tissue plasminogen activator and plasminogen bind to and mediate fibrin clot dissolution, whereas uPA is primarily involved in pericellular proteolysis as it binds to specific cell-surface glycosyl phosphatidylinositol-anchored receptors (uPAR) (Moller, 1993) .
The uPA-uPAR interaction on cancer cell surfaces is a key event that results in increased in vitro matrix degradation and migration (Duffy, 1993; Mignatti and Rifkin, 1993) . In the absence of extracellular proteolysis, inactive uPA binding has been shown to induce cell migration by signal transduction events via uPAR (Busso et al, 1994) . Nevertheless, dissolution of matrix via plasminogen activation at the cell surface is important for metastasis to occur. Indeed, the inhibition of uPA and plasmin by specific inhibitors or antibodies, or antisense inhibition of uPAR resulted in decreased plasminogen activation and hence decreased extracellular matrix degradation in vitro or decreased metastasis in nude mouse models with various cancer cell lines (Baker et al, 1990; Kook et al, 1994) , including human breast cancer cell lines (HolstHansen et al, 1996; Stonelake et al, 1997) . In vitro invasiveness has been correlated with uPA and plasmin activity as well as high uPAR and plasminogen activator inhibitor type 1 (PAI-1) protein levels in human breast cancer cell lines (Holst-Hansen et al, 1996) . Long-term studies have shown that increased primary breast cancer biopsy levels of the uPA antigen are related to shorter disease-free period and reduced survival in women with breast cancer (Duffy, 1993) . It is now apparent that the combined overexpression of uPA, uPAR and plasminogen activator inhibitor type 1 (PAl-1) in human breast carcinoma tissue is associated with breast cancer progression and can also be related to shorter disease-free period and reduced survival (Janicke et al, 1991; Christensen et al, 1996; Costantini et al, 1996; Nielsen et al, 1996) , while elevated PAI-2 levels are related to a favourable prognosis in primary breast cancer (Foekens et al, 1995) .
Plasminogen has been immunologically localized to cell surfaces in sections of human mammary carcinoma tissue (Burtin et al, 1993) and to the invasive front of cutaneous melanoma lesions (De Vries et al, 1996) . Cell-surface localization of plasminogen would be advantageous for cell migration, as the activation of receptor-bound plasminogen to plasmin is enhanced while cell-bound plasmin is protected from circulating inhibitors (e.g. a2-antiplasmin) (Plow and Miles, 1990) . Plasminogen binds to a number of different cell types via its kringle domains within a range of affinities (dissociation constants (Kd) = 0.1-5 gM) and receptor sites per cell (104-108), and various candidate receptors have been identified from endothelial cells (Cesarman et al, 1994) , neurons (Parkkinen and Rauvala, 1991) , monocytoid cells (Miles et al, 1991) and breast cancer cells (Hembrough et al, 1995) . Plasminogen also interacts with several extracellar matrix components, such as type IV collagen (Stack et al, 1992) , and with non-proteinaceous cellular moieties, such as gangliosides (Miles et al, 1989) .
Approximately 20-30% of all human breast cancers overexpress two closely related receptor tyrosine kinases, epidermal growth factor receptor (EGFR) and/or p1 85HER2/neu (c-erbB-2), and this phenotype is associated with more aggressive tumour growth and reduced patient survival (Singleton and Strickler, 1992) . In contrast, breast cancer cell lines that are oestrogen receptor (ER) positive and have little or no EGFR have a fundamentally nonmetastatic phenotype (Lee et al, 1990) . The presence of ER is also inversely related to uPA and uPAR levels in breast carcinomas and cell lines (Mignatti and Rifkin, 1993; Long and Rose, 1996) . In addition, it is apparent that breast cancer cell lines that readily form tumours and metastasize in nude mouse models and/or are invasive in in vitro models of metastases (e.g. MDA-MB-231 cells) (Thompson et al, 1992) tend to be EGFR(+)/erbB-2 protein(+) and ER(-) (Lee et al, 1990) , as well as uPA/uPAR(+) (Holst-Hansen et al, 1996) . Interestingly, EGFR stimulation or cerbB-2 overexpression in human breast cancer cells enhances the expression and secretion of uPA and expression of uPAR (Long and Rose, 1996; Connolly and Rose, 1997) .
The purpose of this study was to characterize the cell-surface plasminogen binding events in three human breast cancer cell lines. We report that in these cell lines, elevated cell-surface lysine-dependent plasminogen binding and plasmin formation is associated with metastatic capacity and other parameters (EGFR/erbB-2 status, ER status, uPA/uPAR status) commonly associated with human breast cancer malignancy. We also found that non-viable cells bound 100-fold more plasminogen than viable cells and that the presence of non-viable cells must be considered when determining cell-surface binding parameters. In addition, a distinct plasminogen receptor profile was evident in the plasma membranes of the breast cancer cell lines, suggesting heterogeneity of plasminogen binding proteins in these cell lines.
MATERIALS AND METHODS Materials
RPMI 1640, L-glutamine and Hank's buffered salt solution were purchased from Trace Biosciences (Castle Hill, NSW, Australia). Fetal calf serum was obtained from CSL (Parkville, Victoria, Australia). Tranexamic acid, E-amino-n-caproic acid (EACA), aprotinin, polyvinyl pyrrolidine (PVP-40), bovine serum albumin (fraction V) (BSA) and fluorescein isothiocyanate (isomer 1) (FITC) were purchased from Sigma Chemical (St Louis, MO, USA). Biotin-X-NHS was from Calbiochem (San Diego, CA, USA). Z-lysine thiobenzylester was from Peninsula Laboratories (CA, USA). Enhanced chemiluminescence (ECL) detection kit was purchased from Amersham International (Buckinghamshire, UK). Molecular weight protein standards were obtained from Novex (San Diego, CA, USA). The Dako LSAB+ kit was from Dako (CA, USA).
Specific proteins and antibodies Human recombinant ax-enolase was prepared as previously described (Andronicos et al, 1997) . Active human uPA was from Serono (Sydney, NSW, Australia). Plasminogen, plasmin, the plasmin-specific substrate Spectrozyme-PL, mouse anti-human uPAR monoclonal antibody (no. 3696) and rabbit anti-human uPAR polyclonal antibody (no. 399R) were purchased from American Diagnostica (Greenwich, CT, USA). Rabbit anti-human plasminogen polyclonal antibody and horseradish peroxidaseconjugated goat anti-rabbit polyclonal antibody were purchased from Calbiochem (San Diego, CA, USA). Mouse anti-human EGFR monoclonal antibody (clone LAI) was obtained from Upstate Biotechnology (Lake Placid, NY, USA), while mouse anti-human Neu (9G6) monoclonal antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). SBU-LCA IgG2a monoclonal antibody against sheep lymphocyte markers was from the Centre for Animal Biotechnology (Melbourne, Victoria, Australia), and FITC-conjugated anti-mouse IgG was from Silenus (Sydney, NSW, Australia).
Cell culture
The human breast cancer cell lines used in this study (MCF-7, MDA-MB-231, T-47D) were gifts from Professor R Sutherland (Garvan Institute of Medical Research, Sydney, NSW, Australia). The cell lines were all routinely cultured in RPMI-1640 supplemented with 10% (v/v) heat-inactivated fetal calf serum. The T-47D cell line was cultured in the above media containing insulin (0.2 IU ml-'). The cells were incubated in a humidified incubator at 37°C with a 5% carbon dioxide-95% air atmosphere.
Whole-cell lysate preparation
Confluent cells were washed with sterile ice-cold phosphatebuffered saline (PBS) and harvested by scraping with a rubber policeman. The cells were incubated with cell lysis buffer [50 mm Tris-HCl (pH 8.0), 150 mm sodium chloride, 4 mM magnesium chloride, 10% glycerol, 5 mm EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate] at 40C for 20 min. The resulting lysates were collected and centrifuged at 14 000 g for 15 min at 4°C and the supernatant stored at -20°C until required.
Membrane preparations Total cellular membrane Confluent cells were washed and harvested by scraping in ice-cold PBS and subjected to hypotonic shock in a small volume of icecold hypotonic buffer [3 mm sodium phosphate (pH 7.4), 5 mm EDTA, 1 mm phenylmethylsulfonyl fluoride]. The suspensions were then sonicated with several 20-s bursts at high power with a Branson Sonifier 250 (CT, USA), checked under a microscope for effective disruption of the cells and then centrifuged at 500 g for 5 min. The supernatant was centrifuged at 46 000 g for 30 min and the resultant supernatant was frozen in aliquots at -70°C. The crude membrane pellet was resuspended in 5 ml of ice-cold 5 mM EDTA/PBS, briefly resonicated, diluted to 50 ml with EDTA/PBS and centrifuged at 46 000 g for 30 min. The resulting membrane pellet was resuspended in 1 ml of EDTA/PBS with brief sonication, then aliquoted and stored at -70°C. Plasma membrane Confluent cells were washed, harvested, subjected to hypotonic shock as above and then homogenized in a Dounce homogenizer. Plasma membranes were then isolated using the aqueous twophase PEG polymer/dextran system as described by Rana and Majumder (1987) .
Western blotting and plasminogen ligand blotting Whole-cell lysates and membrane preparations were boiled in sample buffer, fractionated on 10% or 12% SDS-PAGE gels, and parallel gels were either stained with Coomassie blue or transferred to PVDF membranes at 100 V for 1 h or 30 V overnight at 4°C. For Western blotting, the membranes were washed in TBST [50 mM Tris-HCl (pH 8.0), 150 mm sodium chloride, 0.05% (v/v) , blocked in 10% milk powder/TBST at room temperature for 1-2 h, rinsed in TBST, then incubated with the primary antibody in 2% milk/TBST for 1 h at room temperature. After extensive washing, the membrane was re-blocked for 20 min with 6% milk/TBST and incubated with the appropriate secondary antibody diluted 1:2000 in 2% milk/TBST. After three washes with TBST and one wash with TBS, the immune complexes were detected by ECL.
For ligand blotting, membranes were washed once with TNCM [50 mM Tris-HCl (pH 7.5), 150 mm sodium chloride, 2 mM calcium chloride, 3 mM magnesium chloride] and blocked with TNCM/2% PVP-40 overnight at room temperature. The membranes were then probed with 5 nM glu-plasminogen in the absence or presence of 100 mM EACA in TNCM/PVP-40 containing 0.05% (v/v) Tween 20 (TNCMT) for 45 min and washed for 1 h with three changes of TNCMT. After re-blocking for 30 min, a 1: 2000 dilution of rabbit antiplasminogen polyclonal antibody in TNCMT/PVP-40 was added and incubated with the membrane for 1 h. This was followed by three 5-min washes, re-blocking for O min and probing with a 1:1000 dilution of horseradish peroxidase-conjugated goat anti-rabbit polyclonal antibody in TNCMT/PVP-40 for 1 h. This was followed by three washes with TNCMT and one wash with TNCM. The blots were then developed by ECL.
Urokinase plasminogen activator activity and plasmin activity assays
The activity of uPA in the membrane preparations was measured as described by Coleman and Green (1981) . Briefly, membrane preparations (10 ,ug of protein per well) were preincubated with glu-plasminogen (1 ,UM) for 45 min at 37°C, followed by a further 45-min incubation with the chromogenic plasmin substrate, Zlysine thiobenzylester (170,M). Colour development was read at 414 nm. Standard curves were constructed using uPA. Plasmin activity was measured using the Spectrozyme-PL assay (American Diagnostica; conditions are described in the figure legend). Standard curves for the uPA and plasmin assays were constructed using uPA and plasmin respectively.
Flow cytometry and fluorimetry
Human glu-plasminogen, aprotinin or BSA in PBS were conjugated with FITC as described by Goding (1976) . Unconjugated FITC was separated by a PD-10 gel filtration column equilibrated with PBS/0.1% azide. FITC-glu-plasminogen was able to bind lysine-Sepharose 4B, while FITC-aprotinin was able to inhibit plasmin activity, indicating that FITC conjugation did not inhibit the function of these proteins.
Subconfluent, adherent cells that had been in culture for 48 h without a change of media were harvested by rinsing flasks twice with cold PBS (pH 7.2) and then detaching with 5 mM EDTA/PBS at 37°C for 5 min. For FITC-glu-plasminogen binding assays, cells were washed twice and resuspended in freshly made and chilled binding buffer (Hanks buffered salt solution containing 1 mM Thompson et al (1992) . eBand intensity was scanned and quantified by densitometry ( After incubation for 1 h on ice in the dark, the cells were washed and resuspended in 250 gl of binding buffer containing the nonvital dye propidium iodide (5 gg ml-'). Cell-associated fluorescence was then measured by dual-colour flow cytometry (FACSort, Becton-Dickinson). By using dual-colour flow cytometry it was possible to distinguish between two parameters based on the different fluorochromes, i.e. ligand binding (FITC produces a strong green fluorescence) and cell viability (propidium iodide binds to DNA and dsRNA and produces a strong red colour) (Darzynkiewicz et al, 1994 Invasive and metastatic characteristics of human breast cancer cell lines
Local tissue invasion and metastatic ability of the MDA-MB-23 1, MCF-7 and T-47D cell lines in nude mice has been characterized in detail by Thompson et al (1992) . Only the MDA-MB-231 cell line was found to be invasive and metastatic. To confirm the in vivo characteristics of these cell lines 1-2 x 106 cells per site were injected into the neck region (s.c.) of male 4-to 6-week-old Swiss nu/nu nude mice. Animals were sacrificed when tumours became 2.5 cm in diameter or after 60 days, whichever arose first. Primary tumours and adjacent lymph nodes were excised and examined histologically.
RESULTS

Metastatic phenotypes of human breast cancer cell lines
In order to confirm that the metastatic phenotypes of the human breast cancer cell lines MDA-MB-23 1, MCF-7 and T-47D concurred with published data, the invasive and metastatic ability of these cell lines in a nude mouse model were compared with morphology, EGFR, c-erbB-21neu, ER and uPAR expression, and uPA activity (Table 1 ). These particular characteristics of the three breast cancer cell lines have not been compiled previously in one study but each characteristic was highly comparable to published data from several sources (Lee et al, 1990; Thompson et al, 1992; Hoist-Hansen et al, 1996) . The MDA-MB-231 cells had a spindleshape morphology, were EGFRIneu(+) and ER(-), were invasive and metastatic in vivo and were highly positive for uPAR protein and uPA activity (Table 1 ). In contrast, the MCF-7 and T-47D cell lines had a more epithelial morphology, contained little or no EGFR/neu protein, were ER(+) and were neither invasive nor metastatic in vivo (although MCF-7 cells are known to form tumours in the presence of oestrogen; Thompson et al, 1992) . Interestingly, the levels of plasma membrane and cell-surface uPAR protein were markedly reduced in the MCF-7 (four-to six-fold respectively) and even more so in T-47D (10-to 15-fold respectively) compared with levels in MDA-MB-231 cells. In agreement, a similar pattern was found for plasma membrane uPA activity (at least threefold for MCF-7 and 18-fold for T-47D) compared with plasma membrane levels in MDA-MB-231 cells. The results in Table 1 and intracellular moieties). Density plots of fluorescence intensity due to FITC-glu-plasminogen binding vs propidium iodide uptake were used to establish 'gates' based on viability ( Figure iB ; described in detail in Materials and methods). Cells that excluded the propidium iodide were gated as viable, whereas cells staining with propidium iodide were gated as non-viable ( Figure 1B ). Based on these parameters, fluorescence intensity due to cellsurface specific plasminogen binding only can be presented as histogram plots, as shown in Figure IC . The histogram plots were used to calculate cell-surface lysine-dependent plasminogen binding ( Figure 1A ) and indicated that, while the MCF-7 and T-47D cell lines bound similarly low but detectable amounts of plasminogen (8.0 ± 0.8 and 9.5 ± 2.3 fluorescence units respectively), the MDA-MB-23 1 cell line bound significantly more plasminogen (21.2 ± 3.6 fluorescence units) than either the MCF-7 or the T-47D cell line.
Interestingly, the amount of FITC-glu-plasminogen binding to non-viable cells was consistently two orders of magnitude higher than to viable cells (refer to Figure 1B ) and this was lysine dependent (data not shown). This phenomenon was also found in the MCF-7 and T-47D cell lines (data not shown).
Cell-surface plasminogen binding to MDA-MB-231 cells was lysine-and concentration-dependent, indicating a specific interaction (Figure 2A) . At all plasminogen concentrations tested, binding to MCF-7 and T-47D cells was minimal compared with MDA-MB-23 1 cells (data not shown). The concentrations of plasminogen required to saturate binding [e.g. to saturate binding to pure recombinant cx-enolase, at least 10 tM (-I mg ml-') of plas- invariably present in most cell preparations, regardless of the care taken to prevent cell damage. Nevertheless, when lysine-dependent plasminogen binding curves were transformed into Scatchard plots, the best fit for the data was curvilinear ( Figure 2B ), indicating two classes of binding sites. The Kd values for plasminogen binding to MDA-MB-231 cells were 1.8 ± 0.6 x 10-6 M for the higher affinity site and 2.0 + 0.9 x I04 M for the lower affinity site.
The numbers of binding sites per cell were 5.0 ± 1.6 x 107 and 3.9 ± 1.8 x 109 for the higher and lower affinity sites respectively. This difference in number of binding sites per cell (two orders of magnitude) is comparable to the difference in capacity seen on viable and non-viable cells by flow cytometry (see above and refer to Figure IB) and suggests that the lower affinity sites are attributable to non-viable cell plasminogen binding.
Ligand histochemistry studies
The plasminogen ligand histochemistry technique allowed plasminogen binding capacity to be visualized on viable cells that were attached and spread onto a substrata. The differences seen by flow cytometry between the cell lines (Figures 1 and 2) were reproduced by plasminogen ligand histochemistry with non-permeabilized cells (Figure 3) . The highest amount of positive brown staining was seen in the MDA-MB-23 1 cell line ( Figure 3A ) compared with the MCF-7 ( Figure 3D ) or T-47D ( Figure 3G ) cell lines. In the presence of excess tranexamic acid plasminogen binding was greatly reduced in all three cell lines ( Figure 3B , E and H), confirming that the cell lines bound plasminogen in a lysine-dependent manner. The ligand histochemistry technique also showed that, while staining was diffuse over the cell surfaces, the degree of plasminogen binding within each cell line was heterogeneous. This was especially apparent in the MCF-7 and T-47D cell lines, in which some cells showed distinctive staining while others appeared to be completely negative ( Figure 3D and G). Deliberate permeabilization of the cells resulted in an enhancement of the amount of plasminogen binding that could be C V~~~~~~~~~~~~~~~~~~~~~~~~~~.
. Figure 5 Plasminogen ligand blotting of breast cancer cell whole-cell lysates. Whole-cell lysates (15 gg per lane) and human recombinant a-enolase (r-aenolase, 5 ,ug per lane) were separated by 12% SDS-PAGE under reducing conditions and either stained with Coomassie Blue (A) or transferred and subjected to ligand blotting using 5 nm glu-plasminogen in the absence (B) or presence of 100 mm e-amino-n-caproic acid (C). Blots (B) and (C) were derived from gels run, transferred and probed in parallel and were exposed onto the same piece of autoradiograph film so that a direct comparison could be made between them. Glu-plasminogen binding proteins were detected using an anti-plasminogen polyclonal antibody. Figure 1B) . Interestingly, while the permeabilized MDA-MB-23 1 cells ( Figure 4A ) still appeared to bind more plasminogen than the permeabilized MCF-7 ( Figure 4D ) and T-47D ( Figure 4F ) cell lines, this difference between the three cell lines was not as apparent as in the non-permeabilized cells (Figure 3 ). This may be as a result of the sheer magnitude of plasminogen binding in permeabilized cells, which has the effect of diminishing the differences in plasminogen binding capacity between the cell lines.
Total cellular and membrane-associated plasminogen binding proteins in the three breast cancer cell lines Several bands were detected in ligand blots of whole-cell lysates from the breast cancer cell lines ( Figure 5 ). Of these, two were major plasminogen binding bands (apparent molecular masses 50 kDa and British Journal of Cancer (1998) 30 kDa) and were present at similar levels in all three cell lines ( Figure 5B ). These bands corresponded to plasminogen binding proteins because the lysine analogue EACA completely abolished the binding of plasminogen to these proteins ( Figure SC) .
Ligand blots of plasma membrane proteins indicated a distinct plasminogen binding protein profile on each of the three cell lines (Figure 6 ). The MCF-7 plasma membranes contained three major bands with apparent molecular masses of 57 kDa, 47 kDa and 33 kDa, as well as two minor bands of 40 kDa and 36 kDa ( Figure  6B ). The 47-kDa and the 33-kDa bands in the MCF-7 plasma membranes ( Figure 6B ) corresponded to the 50-kDa and 30-kDa bands, respectively, in the MCF-7 whole-cell lysate ( Figure 5 ). While the MDA-MB-231 and T-47D plasma membranes did not contain detectable amounts of the 57-kDa or 47-to 50-kDa bands seen in the MCF-7 plasma membranes, the 30-to 33-kDa band was present in all plasma membranes as a major band ( Figure 6B ). The MDA-MB-231 plasma membranes contained two other major bands with apparent molecular masses of 36 kDa and 26 kDa ( Figure 6B ). The T-47D plasma membranes also contained the 36-kDa band but in lower concentration than in the MDA-MB-231 plasma membranes ( Figure 6B ). In all ligand blots the plasminogen binding protein r-ox-enolase (Andronicos et al, 1997 ) was used as a positive control. In each case the presence of EACA inhibited plasminogen binding to the protein (Figures SC and 6C ).
Plasmin generation is associated with high plasminogen binding capacity and uPA activity
The ability to generate plasma membrane-associated plasmin activity was compared between the three breast cancer cell lines (Figure 7 ). Not surprisingly, the MDA-MB-231 cells, which have the highest plasminogen binding capacity and highest endogenous uPA activity, were highly efficient at generating plasmin. This activity was dependent on the presence of plasminogen and was completely inhibited by preincubation with the high-affinity plasmin inhibitor aprotinin. At a plasminogen concentration of 0.5 jtM, there was no detectable plasmin specific activity in either the MCF-7 or the T-47D plasma membranes compared with 110 pmol min-' mg-' in the MDA-MB-23 1 plasma membranes. At higher concentrations of plasminogen and membrane protein, a small amount of plasmin specific activity could be detected in the MCF-7 and T-47D plasma membranes, however this was minimal compared with that detected for MDA-MB-23 1 plasma membranes (data not shown).
In order to show that plasmin was generated on the surfaces of viable MDA-MB-231 cells, dual-colour flow cytometry was used to establish 'gates' based on viability (refer to Figure lB and Materials and methods) using FITC-aprotinin as the ligand. The use of FITC-aprotinin as a specific detector of plasmin activity had been previously described (Ellis et al, 1987) . The inset to Figure 7 show that FITC-aprotinin bound to viable cells but only when preincubated with plasminogen, suggesting that MDA-MB-231 cells were capable of activating receptor-bound plasminogen on the cell surface.
DISCUSSION
This study demonstrates that the spindle-shaped, EGFR (+)Ieu(+), ER(-) and metastatic MDA-MB-231 cells were not only associated with high uPA activity and uPAR overexpression but that they also had an increased capacity to bind and activate cell-surface plasminogen compared with the more differentiated, nonmetastatic cell lines MCF-7 and T-47D. Our results suggest that expression of cell-surface plasminogen receptors plays a part in regulating the plasminogen activation cascade and may contribute to the metastatic phenotype of the MDA-MB-23 1 cell line.
Dual-colour flow cytometry was used initially as a means to identify cell surface-specific plasminogen binding. However, this technique also revealed that both viable and non-viable cells could bind FITC-glu-plasminogen in a lysine-dependent manner. Moreover, non-viable cells bound two orders of magnitude more plasminogen than viable cells. This was confirmed by ligand histochemistry, which showed that biotinylated plasminogen binding capacity was substantially increased in all cell lines after permeabilization. This is an important finding as it is very difficult to harvest adherent cells and maintain them throughout experimental procedures at 100% viability (we consistently found that 10%, sometimes up to 20%, of the cells were non-viable as assessed by propidium iodide uptake by the time cells were analysed by flow cytometry) and suggests that even a small proportion of non-viable cells could affect evaluation of authentic cell-surface plasminogen binding capacity if viability status is not considered.
Scatchard plots of plasminogen binding data to MDA-MB-23 1 cells using a single-colour fluorescence technique resulted in curvilinear plots that are suggestive of two classes of binding sites.
Plasminogen binding to breast cancer cells 1595
Curvilinear Scatchard plots of plasminogen binding have been reported previously for endothelial cells using a radiolabelled plasminogen binding technique (Ganz et al, 1991) . The higher-affinity binding site in the MDA-MB-231 cells had an average Kd of 1.8 gM and 5.0 x 107 binding sites per cell, while the lower affinity one had an average Kd of 200 gM and 3.9 x 109 binding sites per cell. The affinity and capacity of the higher-affinity site are similar to that reported for many cell types determined by radiolabelled glu-plasminogen techniques (Plow and Miles, 1990; Hembrough et al, 1995) and are within physiological limits as plasminogen is found in the circulation at 2 gM. The capacity of the higher-affinity site is two orders of magnitude higher than the lower-affinity siteexactly the difference seen in capacity between viable and nonviable cells by dual-colour flow cytometry. As non-viable cells were present in all fluorimetry experiments (up to 15% of total cell sample), it is likely that the lower-affinity, very-high-capacity binding sites are due to non-viable cells. The affinity and capacity of these non-viable cells implies that it would be hard to saturate binding. Indeed the non-viable cell binding curves (generated by dual-colour flow cytometry; data not shown) were linear at the concentrations of plasminogen used for assessing cell-surface binding (refer to Figure 2A ). Nevertheless, while binding to nonviable cells may not be physiologically relevant, taken together, our results suggest that plasminogen binding to non-viable cells is so large that subtle or even significant differences in cell surfacespecific plasminogen binding capacity between cells can be missed when measured and analysed with techniques that cannot distinguish between viable and non-viable cells.
Our results also suggest that there are many more intracellular plasminogen binding moieties than cell surface ones, regardless of the cell-surface binding capacity. The 50-kDa plasminogen binding protein present in the whole-cell lysates of MDA-MB-231, MCF-7 and T-47D cells may account for at least some of the increase in plasminogen binding capacity of both the MDA-MB-231 and the T-47D cell line upon permeabilization. While all of the cell lines expressed plasma membrane-associated plasminogen binding proteins, the plasminogen ligand blots gave no information about the orientation of plasminogen binding proteins within the plasma membranes of intact cells. Therefore, the presence of these proteins in the plasma membrane does not necessarily mean that they would be oriented on the cell surface in such a way that they could bind pericellular plasminogen. As viable or nonpermeabilized MCF-7 and T-47D cells had minimal cell-surface plasminogen binding capacity compared with viable or nonpermeabilized MDA-MB-23 1 cells, perhaps only a small proportion of the MCF-7 and T-47D plasma membrane-associated proteins are physiologically available to bind extracellular plasminogen. Upon permeabilization a greater proportion of these proteins may also become available for plasminogen binding in the MCF-7 and T-47D cells. It is also possible that non-proteinaceous binding moieties, such as gangliosides (Miles et al, 1989) , may account for a significant proportion of the differences in cellsurface plasminogen binding between the cell lines.
Nevertheless, the ligand blot data indicate that more than one protein moiety contributes to total cellular plasminogen binding capacity in these cell lines. The intermediate filament protein cytokeratin 8 and the glycolytic enzyme ox-enolase are two potentially important receptors that have been isolated from the plasma membranes of rat hepatocytes (Hembrough et al, 1995) , the lymphoid monocytic cell line U-937 (Miles et al, 1991) and embryonic rat neurons (Nakajima et al, 1994) . Cytokeratin 8 has been localized to the cell surface of human breast cancer cells (Hembrough et al, 1995 (Hembrough et al, , 1996 , and an ct-enolase-like protein with plasminogen binding ability was isolated from total cell lysates of two human breast cancer cell lines (Lopez-Alemany et al, 1994) . We have previously demonstrated that the glycolytic enzyme Xenolase is an authentic plasminogen binding protein and that it is present as a 47-kDa protein in whole-cell lysates of various human cancer cell lines, including the breast cancer cell lines used in this study (Andronicos et al, 1997) . Using a ['251]plasminogen overlay assay, Hembrough et al (1996) showed the presence of several plasminogen binding proteins in the cytoplasm and plasma membrane fractions of various breast cancer cells. Moreover, they showed the presence of a major 55-kDa plasma membrane-associated plasminogen binding protein in MCF-7 cells, which they identified as cytokeratin 8. Thus, it is possible that the 47-to 50-kDa and the 57-kDa plasminogen binding proteins detected in the current study may be x-enolase and cytokeratin 8 respectively. The possible identity of the other plasminogen binding proteins remain unclear. However, the molecular mass of the 30-to 33-kDa protein is similar to that of another plasminogen binding protein, amphoterin (Parkkinen and Rauvala, 1991) .
Thus it is clear that a number of proteinaceous and possibly non-proteinaceous moieties are likely to contribute to cell-surface plasminogen binding. It is therefore difficult to design specific experiments aimed at establishing a direct relationship between plasminogen binding capacity and metastatic potential without identifying all of the plasminogen binding moieties on the breast cancer cell lines. However, Stonelake et al (1997) recently demonstrated that, in the presence of plasminogen, MDA-MB-231 and other metastatic breast cancer cell lines, unlike non-metastatic cell lines, such as MCF-7 and T-47D, had the ability to degrade human endothelial basement membrane and that this activity was significantly inhibited by specific uPA or plasmin inhibitors. These authors also demonstrated a similar inhibitory effect by lysine analogues and attributed this result to an inhibition of plasminogen binding. These results strongly corroborate our data, which indicates that the plasminogen binding capacity of breast cancer cells modulates plasmin activity in the presence of uPA and, taken together, establishes a relationship between the plasminogen binding capacity of breast cancer cells and their metastatic potential, at least in an in vitro model.
The differences in cell-surface plasminogen binding between the metastatic MDA-MB-231 cells vs the non-metastatic MCF-7 and T-47D cells are possibly related to the ability of cells to target some or all of their plasminogen binding proteins to the cell surface. One possible mechanism may be linked to the difference in uPA/uPAR status between the cell lines. Incubation of the WISH epithelial cell line, which expresses high levels of uPAR but undetectable levels of uPA, with inactive uPA resulted in the phosphorylation and redistribution of the cytoskeletal components cytokeratin 8 and 18 (Busso et al, 1994) . From this, it was suggested that signal transduction pathways via the uPAR GPI anchor are involved in cell migration (Busso et al, 1994) . As cytokeratin 8 has been shown to be a plasminogen receptor associated with the external surfaces of human breast cancer cells (Hembrough et al, 1995 (Hembrough et al, , 1996 , signal transduction events associated with uPAR expression may be one mechanism that leads to an increased capacity of breast cancer cells, such as the MDA-MB-231 cells, to bind cell-surface plasminogen.
It is conceivable that variations in the activity of intracellular signalling proteins due to EGFR and erbB-21neu expression may British Journal of Cancer (1998) 77(10), [1586] [1587] [1588] [1589] [1590] [1591] [1592] [1593] [1594] [1595] [1596] [1597] 0 Cancer Research Campaign 1998 initiate events that lead to the translocation of proteins within the cell (Milligan et al, 1995) and may in some way affect the localization of proteins that can act as plasminogen receptors if placed in the correct orientation at the cell surface. Amino-or carboxyterminal lysines appear to be the only feature common and necessary to all candidate plasminogen binding proteins. Any intracellular protein with an amino-or carboxy-terminal lysine that is also subject to the above modifications could be translocated to the outer surface of the plasma membrane and act as a plasminogen receptor.
Other markers whose cellular expression correlates with metastatic potential have been identified in human breast cancer cell lines. These include matrix metalloproteinase-2 (Azzam et al, 1993) , vimentin (Thompson et al, 1992) and surface glycoproteins such as CD44 (Culty et al, 1994) . However, a review of the literature indicates that overexpression of components of the plasminogen activation cascade play an important role in breast cancer invasion and metastasis. While stromal cells adjacent to cancer cells in breast cancer tissue may contribute to invasion, by expressing uPA and/or uPAR for example (Christensen et al, 1996; Costantini et al, 1996; Nielsen et al, 1996) , our data and that of others (Holst-Hansen et al, 1996; Stonelake et al, 1997) clearly show that breast epithelial cells with a metastatic phenotype have the capacity to efficiently convert plasminogen to plasmin. A combination of studies suggests that the concentration and spatial distribution of the combination of uPA, uPAR, PAl-1 and PAI-2 expression in human breast carcinomas allow a better indication of degree of malignancy (Foekens et al, 1995; Christensen et al, 1996; Costantini et al, 1996) . The results presented in this paper strongly suggest that another component of the plasminogen activation cascade, i.e. plasminogen receptors, is important and their role in human breast cancer should be further characterized.
